Abbott price target raised to $133 from $131 at Piper Sandler

Piper Sandler analyst Adam Maeder raised the firm’s price target on Abbott to $133 from $131 and keeps an Overweight rating on the shares. The firm notes Abbott reported Q3 results that beat Street estimates for reported revenue and adjusted EPS–though underlying top-line growth did come in shy of models. Regarding full year 2024 guidance, Abbott reaffirmed its top-line growth outlook of +9.5%-10.0% and increased its adjusted EPS guidance by 1c to $4.64-$4.70.